- Abstract:
-
In forced-swim tests in mice and rats, the novel D(3)/D(2) receptor agonist S32504 [(+)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] dose-dependently (0.04-2.5 mg/kg) and stereospecifically suppressed immobility compared with its enantiomer S32601 [(-)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth-[1,2-b]-1,4-oxazine]. Ropinirole was less potent than S32504 in this procedure, and it was likewise less potent than S32504 (0.04-2.5 mg/kg) in a...
Expand abstract - Publication status:
- Published
- Journal:
- The Journal of pharmacology and experimental therapeutics
- Volume:
- 309
- Issue:
- 3
- Pages:
- 936-950
- Publication date:
- 2004-06-05
- DOI:
- EISSN:
-
1521-0103
- ISSN:
-
0022-3565
- URN:
-
uuid:7c5ecafa-1101-42c8-b170-299341bb0f14
- Source identifiers:
-
185237
- Local pid:
- pubs:185237
- Language:
- English
- Keywords:
- Copyright date:
- 2004
Journal article
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record